Payment overview · 2025
General Payments
$544.14
24 reported records · 14 companies
Healthcare provider profile · identity verified
Abel C. Toledo, M.D.
Allopathic & Osteopathic Physicians|General Practice · CHULA VISTA, CA · NPI 1518059799
Verified facts
What the public records show
CMS Open Payments records show Abel C. Toledo, M.D. received $544.14 in general payments during 2025 across 24 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 14.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $80.85 | 14.9% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $76.41 | 14.0% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $62.25 | 11.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $43.83 | 8.1% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $38.55 | 7.1% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.72 | 6.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.39 | 6.1% | 2 | 2025 |
| BioWound Solutions, Inc. | Unresolved — no canonical attribution shown | $32.62 | 6.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $29.94 | 5.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $27.82 | 5.1% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $26.20 | 4.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.90 | 4.2% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $18.78 | 3.5% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $16.88 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $544.14 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $76.41 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $62.25 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $43.83 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $43.83 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $38.55 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $33.72 | 1 | 2025 |
Source payment records
|
|||||
| bio-ConneKt Normalized: bio connekt |
Device | BioWound Solutions, Inc. | $32.62 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $29.94 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.64 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $27.82 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.90 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 73 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 48 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 104 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
48 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
104 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
104 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
150 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
73 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 843 | 275 |
| Metformin Hcl | Metformin Hcl | 507 | 159 |
| Amlodipine Besylate | Amlodipine Besylate | 434 | 136 |
| Lisinopril | Lisinopril | 431 | 143 |
| Losartan Potassium | Losartan Potassium | 345 | 123 |
| Omeprazole | Omeprazole | 314 | 88 |
| Tamsulosin Hcl | Tamsulosin Hcl | 299 | 98 |
| Gabapentin | Gabapentin | 284 | 96 |
| Ozempic | Semaglutide | 273 | 58 |
| Levothyroxine Sodium | Levothyroxine Sodium | 263 | 78 |
| Simvastatin | Simvastatin | 238 | 59 |
| Alendronate Sodium | Alendronate Sodium | 180 | 54 |
| Finasteride | Finasteride | 161 | 46 |
| Trulicity | Dulaglutide | 150 | 35 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 146 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 132 | 40 |
| Pioglitazone Hcl | Pioglitazone Hcl | 126 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 121 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 111 | 37 |
| Trazodone Hcl | Trazodone Hcl | 111 | 37 |
| Sertraline Hcl | Sertraline Hcl | 107 | 36 |
| Jardiance | Empagliflozin | 104 | 34 |
| Ibuprofen | Ibuprofen | 99 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 98 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 93 | 32 |
| Furosemide | Furosemide | 91 | 31 |
| Famotidine | Famotidine | 88 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 85 | 31 |
| Tramadol Hcl | Tramadol Hcl | 85 | 21 |
| Metformin Hcl Er | Metformin Hcl | 82 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 80 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 27 |
| Carvedilol | Carvedilol | 79 | 25 |
| Mirtazapine | Mirtazapine | 74 | 24 |
| Eliquis | Apixaban | 73 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 70 | 31 |
| Allopurinol | Allopurinol | 67 | 18 |
| Chlorthalidone | Chlorthalidone | 65 | 20 |
| Nifedipine Er | Nifedipine | 65 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 23 |
| Januvia | Sitagliptin Phosphate | 58 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 57 | 15 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 56 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | 12 |
| Atenolol | Atenolol | 53 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 18 |
| Naproxen | Naproxen | 49 | 22 |
| Farxiga | Dapagliflozin Propanediol | 48 | 12 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 47 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 46 | 16 |
| Bupropion Xl | Bupropion Hcl | 44 | 11 |
| Lorazepam | Lorazepam | 41 | 12 |
| Montelukast Sodium | Montelukast Sodium | 39 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 39 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | 14 |
| Potassium Chloride | Potassium Chloride | 38 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | suppressed |
| Alprazolam | Alprazolam | 35 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | 11 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | 12 |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Latanoprost | Latanoprost | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 13 |
| Telmisartan | Telmisartan | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 25 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 24 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | 11 |
| Sucralfate | Sucralfate | 23 | suppressed |
| Prednisone | Prednisone | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lamotrigine Er | Lamotrigine | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Proair Respiclick | Albuterol Sulfate | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
| Xeljanz Xr | Tofacitinib Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $544.14 · 24 records | Boehringer Ingelheim Pharmaceuticals, Inc. | AIRSUPRA, APTIMA, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, PURIFIED CORTROPHIN GEL, REPATHA, REXULTI, ZEPBOUND, bio-ConneKt | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error